Volume 26 (2023)
Volume 25 (2022)
Volume 24 (2021)
Volume 23 (2020)
Volume 22 (2019)
Volume 21 (2018)
Volume 20 (2017)
Volume 19 (2016)
Volume 18 (2015)
Volume 17 (2014)
Volume 16 (2013)
Volume 15 (2012)
Volume 14 (2011)
Volume 13 (2010)
Volume 12 (2009)
Volume 11 (2008)
Volume 10 (2007)
Volume 9 (2006)
Volume 8 (2005)
Volume 7 (2004)
Volume 6 (2002)
Volume 5 (2002)
Volume 4 (2000)
Volume 3 (1999)
Volume 2 (1998)
Volume 1 (1997)
Mucocutaneous adverse effects following COVID-19 vaccination: a case series with a comprehensive review of the literature

Parvaneh Hatami; Zeinab Aryanian; Hamed Nicknam Asl; Azadeh Goodarzi

Volume 24, Issue 4 , December 2021, , Pages 331-338


  Since coronavirus disease 2019 (COVID-19) vaccines were approved without long-term monitoring, tracking their adverse effects appears to be necessary. Mucocutaneous adverse events are of great importance due to their visibility and the potential effect on inducing fear in patients leading to vaccine ...  Read More

Association of pityriasis rosea with Human Herpesvirus-6

Banihashemi Mahnaz; Javidi Zari; Khani Fatemeh; Ghiasi-Moghadam Taghi; Ghaffarzadegan Kamran; Hashemzadeh Sara

Volume 17, Issue 4 , 2014, , Pages 122-125

  Background: Pityriasis rosea (PR) is a common papulosquamousskin disorder that is suspected to have an infectious etiology.We aimed to study the role of human herpesvirus-6 (HHV-6) inthe pathogenesis of PR.Method: We used immunohistochemical (IHC) assays to detectHHV-6 in patients with PR. Fifty-one ...  Read More

Atypical Pityriasis Rosea with a Target-Shape Herald Patch

Tehranchi-nia Zohreh; Rahimi Hoda

Volume 13, Issue 1 , 2010, , Pages 24-26

  Pityriasis rosea (PR) is an acute, self-limiting papulosquamous exanthem. A number of atypical variants of PR, regarding morphology and distribution of the lesions or severity of the symptoms, may be observed. Herein, we present the first case of atypical PR with hypopigmented lesions and a target-shape ...  Read More

Azithromycin in Pityriasis Rosea: A Double-Blind, Placebo-Controlled Clinical Trial

Ehsani Amir Hooshang; Toosi Siavash; Noormohamadpour Pedram; Hosseini Mahboubeh; Nazeman Leila

Volume 11, Issue 4 , 2008, , Pages 143-146

  Background: Pityriasis rosea is an inflammatory skin disorder with a known response to erythromycin. Considering similarities between erythromycin and azithromycin and lesser adverse effects of the latter, in a pilot study, we gave azithromycin to seven patients with pityriasis rosea and observed a noticeable ...  Read More

A descriptive study on patients with Pityriasis Rosea admitted to Dermatology Clinic at Qaem Hospital, Mashhad, 2000-02

SZ Famili; SM Dadkhah; S Ebrahim Zadeh

Volume 8, Issue 4 , 2005, , Pages 287-292

  Background and objective: Pityriasis rosea (PR) is a transient skin disease with a distinct appearance that is prevalent throughout the world and is more frequently seen in winter. Despite the reported epidemiological evidence, which account for an infective agent, this has not been proved, yet. This ...  Read More

The efficacy of oral Erythromycin in the treatment of patients with Pityriasis Rosea: A randomized double-blind, placebo-controlled clinical trial

M Akhyani; H Mortazavi; M Izadi; AH Ehsani

Volume 7, Issue 1 , 2003, , Pages 14-18

  Background: Pityriasis rosea is an acute, inflammatory and self-limited disease, which is characterized by a primary scaly plaque (Herald patch) followed by a generalized, symmetrical papulosqumous eruption (Mostly on trunk and proximal extremities). Objective: To determine the efficacy of erythromycin ...  Read More